MILWAUKEE, Sept. 10, 2024 /PRNewswire/ -- Ademi LLP announces that a class action lawsuit has been filed on September 9, 2024 in the United States District Court for the Southern District of New York, captioned Mitchell v. Taro Pharmaceutical Industries Ltd., et al., Case No. 7:24-cv-06818, on behalf of a class of individuals and entities (the "Class") that held securities of Taro Pharmaceutical Industries Ltd. (NYSE: TARO), asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1 ...

Combined entity is better positioned to compete in increasingly competitive generics industry Sun Pharma is the world's leading specialty generics company with a presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. Sun Pharma's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% ...

MUMBAI, India and NEW YORK, May 23, 2024 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associates referred as "Sun Pharma") and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today announced that the merger agreement between Taro and Sun Pharma was approved by the affirmative vote of Taro shareholders (including a vote of the majority of shares held by Taro shareholde ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 TARO PROVIDES RESULTS FOR YEAR ENDED MARCH 31, 2024 Hawthorne, NY, May 20, 2024 - Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today provided unaudited financial results for the quarter and year ended March 31, 2024. Quarter ended March 31, 2024 Highlights ─ compare ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number 001-35463 Taro Pharmaceutical Industries Ltd. (Translation of registrant's name into English) 14 Hakitor Street, Haifa Bay 2624761, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cove ...

Financial Performance - Net sales for the quarter ended September 30, 2023, were $148.2 million, an increase from $130.5 million in the same quarter of 2022, reflecting a mid-single-digit growth when excluding a one-time gross-to-net adjustment[7] - Gross profit for the quarter was $73.6 million, representing 49.7% of net sales, compared to $47.0 million or 36.0% of net sales in the prior year quarter[7] - Operating income for the quarter was $4.7 million; excluding one-time charges, operating income was $10.9 million compared to an operating loss of $(6.8) million in the prior year[7] - Net income for the quarter was $8.5 million, compared to a net loss of $(2.8) million, resulting in earnings per share of $0.23 compared to a loss per share of $(0.07)[7] - For the six months ended September 30, 2023, net sales were $307.1 million, an increase of $19.9 million or 6.9% from $287.2 million in the same period of 2022[7] - Net income for the six months ended September 30, 2023, was $18,581 million, an increase from $11,266 million in the same period of 2022, representing a growth of 65.5%[21] Expenses - Research and development (R&D) expenses increased to $14.3 million, up $2.8 million primarily due to increased clinical studies[7] - Selling, marketing, general and administrative expenses (SMG&A) totaled $54.5 million, which included one-time charges of $6.1 million; excluding these, SMG&A was $48.4 million compared to $42.3 million in the previous year[7] Cash Flow and Liquidity - Net cash provided by operations for the six months ended September 30, 2023, was $55.3 million, compared to net cash used in operations of $37.7 million for the same period in 2022[15] - Cash and cash equivalents at the end of the period increased to $269,011 million from $175,191 million, reflecting a rise of 53.5%[21] - The company reported a decrease in trade receivables, net, of $20,927 million, compared to an increase of $2,071 million in the previous year[21] - The net cash used in investing activities was $59,866 million, compared to a net cash used of $36,039 million in the same period last year[21] - Cash paid for income taxes during the year was $6,232 million, compared to $3,091 million in the previous year, indicating an increase of 101.5%[21] Assets and Liabilities - As of September 30, 2023, cash and cash equivalents, short-term bank deposits, and marketable securities increased by $40.2 million to $1.3 billion from March 31, 2023[15] - Total assets as of September 30, 2023, were $2.12 billion, with total liabilities of $371.9 million, resulting in shareholders' equity of $1.75 billion[19] - The company reported a decrease in goodwill and intangible assets by $250 million, which was not present in the previous year[21] Investments - The company made a significant investment in marketable securities, with proceeds of $73,716 million, up from $15,516 million in the prior year[21] - The company had non-cash investing transactions for the purchase of property, plant, and equipment included in accounts payable amounting to $1,097 million[21] Exchange Rate Impact - The effect of exchange rate changes on cash and cash equivalents resulted in a decrease of $643 million[21]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____ TARO PROVIDES RESULTS FOR THE QUARTER ENDED JUNE 30, 2023 Hawthorne, NY, July 26, 2023 - Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today p ...

Competition and Market Dynamics - The pharmaceutical industry is highly competitive, impacting product prices, market share, revenue, and profitability[33]. - The company faces risks from competitors with greater financial and R&D resources, which may hinder its ability to differentiate products and maintain market share[34]. - The company anticipates increased competition and price erosion as new entrants and advanced technologies emerge in the market[40]. - Revenue and profits from individual generic products typically decline as competitors introduce their own equivalents[46]. - The company faces intense competition from larger firms such as Novartis and Teva, which possess greater resources and market recognition[211]. Regulatory and Compliance Challenges - Regulatory compliance is extensive and can delay or prevent marketing of products, impacting financial performance[48]. - Delays in obtaining necessary regulatory approvals could adversely impact the company's ability to market its products[52]. - The company must comply with adverse event reporting requirements across jurisdictions, with potential penalties for non-compliance[57]. - The company is subject to significant civil and criminal penalties under the federal False Claims Act for presenting false claims to the government[72]. - The company is subject to extensive pharmaceutical industry regulations, which may impede marketing and sales of products[167]. Pricing and Profitability Pressures - Sales volume and prices may decline due to consolidation among wholesalers and retail pharmacy industries, increasing pricing pressures[37]. - Pricing pressures from political and social scrutiny may adversely affect the company's profitability and financial condition[42]. - The minimum Medicaid rebate rate has increased from 15.1% to 23.1% of AMP for most drugs approved under a new drug application, impacting profitability[66]. - Legislative changes under the Inflation Reduction Act could impose greater pricing pressures on the company's products, including new rebate obligations[61]. - Government price control policies in Israel can materially affect profitability, as all pharmaceutical products sold are subject to government price controls[161]. Operational Risks and Supply Chain Issues - The company must monitor inventory levels closely to avoid excess stock and potential financial losses from product returns[43]. - The company has experienced increased volatility in volumes due to global supply chain issues, impacting production and distribution processes[95]. - Regulatory approvals for alternative suppliers of raw materials may be lengthy, and interruptions in supply could adversely affect operations[96]. - The company relies on third-party manufacturers and logistic service providers, and any failure in these relationships could delay product delivery and harm financial results[84]. - The company is relocating its operations to Hawthorne, New York, which may incur transition costs and disrupt business operations[145]. Legal and Litigation Risks - The company faces potential liabilities from governmental investigations and litigation related to sales and marketing practices, which could result in material penalties[86]. - The company may incur significant costs related to litigation over patent rights, which could affect its ability to manufacture and sell products[127]. - The company has faced risks related to potential litigation regarding the proposed transaction, which could distract management and adversely affect operations[181]. Financial Performance and Market Conditions - For the year ended March 31, 2023, total consolidated net sales were $572.95 million, a slight increase from $561.35 million in 2022 and $548.97 million in 2021[200]. - In the U.S., sales accounted for 63% of total consolidated net sales, down from 67% in 2022 and 70% in 2021, indicating a shift in revenue distribution[200]. - The company estimates future charges against wholesaler accounts receivable, and inaccuracies in these estimates could adversely impact financial results[90]. - The market price of the company's ordinary shares has been volatile, influenced by variations in quarterly operating results and announcements of new products[136]. - Current economic conditions, including rising inflation and interest rates, may adversely affect the company's operations and financial results[139][141]. Cybersecurity and Data Privacy - The company has faced cybersecurity threats, including a significant incident on March 1, 2023, involving data breaches and theft of company and personal data, which impacted business operations and revenues[112]. - The company has invested heavily in information technology and data security, but acknowledges that breaches and unauthorized disclosures could adversely affect business operations and financial results[113]. - The evolving legal framework regarding data privacy and security may require significant resources for compliance, potentially impacting operational practices and costs[114]. - The company has implemented enhanced security measures and is working on long-term improvements to its cybersecurity infrastructure following the recent incident[112]. Research and Development - The company is investing in research and development for new proprietary products, but these efforts are subject to significant risks and uncertainties[100]. - The approval process for pharmaceutical products has become more rigorous and costlier in recent years, with no assurance of timely approvals[223]. - The time from product discovery to commercial launch is substantial, with multiple stages that may encounter obstacles, increasing costs and risks of abandonment[99]. Environmental and Climate Risks - The company must comply with extensive environmental regulations, which could lead to liability for damages or increased operational costs[80]. - The company is exposed to risks related to climate change regulations, which could increase costs and negatively impact its reputation if not managed properly[81]. - The company is subject to environmental regulations at its Haifa Bay manufacturing facility, which may result in penalties if compliance is not met[159]. Human Resources and Operational Stability - Attracting and retaining key personnel is critical for the company's success, and failure to do so could adversely affect its financial position and market value[144][148]. - The company may face disruptions due to compulsory military service for employees, which could impact operations during periods of military conflict[154]. - Strikes and work stoppages in Israel may disrupt operations and affect the ability to deliver products and receive raw materials[158].

Financial Performance - Net sales for the quarter ended March 31, 2023, were $146.6 million, an increase of $3.3 million or 2.3% compared to the same quarter in 2022[7] - Gross profit for the year ended March 31, 2023, was $268.3 million, representing 46.8% of net sales, a decrease of $24.8 million from the previous year[7] - Operating income for the year was $17.7 million, down from $63.5 million, with a significant impact from prior year settlements and loss contingencies of $61.4 million[7] - Net income attributable to Taro for the year was $25.4 million, compared to $58.3 million in the previous year, resulting in earnings per share of $0.68 compared to $1.55[7] - Net income for the twelve months ended March 31, 2023, was $25,445 million, a decrease of 56.4% compared to $58,266 million in 2022[17] Expenses - Research and development (R&D) expenses for the year were $52.2 million, a decrease of $2.3 million compared to the prior year[7] - Selling, general and administrative (SG&A) expenses increased by $84.7 million to $198.4 million for the year ended March 31, 2023[7] - The company incurred $4,175 million in cash paid for income taxes during the year, down from $7,753 million in the previous year[17] Cash Flow and Liquidity - Cash flow provided by operations for the year was $31.8 million, a significant improvement from cash used in operations of $158.7 million in the prior year[7] - Cash flows from operating activities provided $31,750 million, a significant recovery from a cash outflow of $158,698 million in the previous year[17] - Cash and cash equivalents at the end of the period were $154,495 million, down from $251,134 million at the beginning of the period, reflecting a decrease of 38.5%[17] - As of March 31, 2023, total cash and cash equivalents, short-term bank deposits, and marketable securities amounted to $1.3 billion, consistent with the previous year[7] Investments and Assets - The company reported a net cash used in investing activities of $125,556 million, compared to $170,581 million in the prior year, indicating a reduction of 26.4%[17] - The company experienced a decrease in trade receivables, net, amounting to $37,482 million, compared to a decrease of $6,229 million in the previous year[17] - The company reported an increase in inventories, net, of $16,922 million, compared to an increase of $2,082 million in the previous year[17] - The company had a realized loss on the sale of long-lived assets of $136 million, down from $689 million in the previous year[17] - The company did not engage in any acquisitions during the year, contrasting with a cash outflow of $91,872 million for acquisitions in the previous year[17] - The company reported a decrease in cash received for income taxes to $14,156 million from $2,351 million in the previous year[17] Strategic Focus - The company anticipates continued focus on R&D and market expansion strategies in the upcoming fiscal year[10] - Taro's management emphasizes the importance of navigating regulatory challenges and market conditions to achieve future growth[10]

Financial Performance - Net sales increased by $9.6 million, or 6.5%, to $156.7 million compared to the same quarter last year[8] - Gross profit was $81.6 million, representing 52.1% of net sales, down from 52.8% in the prior year[8] - Operating income was $14.0 million, or 8.9% of net sales, compared to an operating loss of $(19.2) million in the prior year[8] - Net income attributable to Taro was $14.1 million, resulting in earnings per share of $0.37, compared to a net loss of $(18.8) million and a loss per share of $(0.50) in the prior year[8] - Net income for the quarter ended June 30, 2022, was $14,079, compared to a net loss of $18,767 in the same quarter of 2021[19] Expenses - Research and development (R&D) expenses decreased by $1.4 million to $11.5 million[8] - Selling, marketing, general and administrative expenses increased by $32.1 million to $56.1 million[8] - The company reported a depreciation and amortization expense of $6,978, an increase from $6,346 in the previous year[19] - The company paid $2,410 in income taxes during the year, down from $3,333 in the previous year[19] Cash Flow and Liquidity - Cash flow used in operations for the quarter was $58.0 million, with cash flow provided by operations at $9.6 million, down from $44.0 million in the prior year[8] - Cash flows from operating activities resulted in a net cash used of $58,028, a significant decrease from the net cash provided of $43,993 in the prior year[19] - Cash and cash equivalents at the end of the period were $225,801, down from $614,888 at the beginning of the period[19] - As of June 30, 2022, cash and cash equivalents and marketable securities decreased by $74.7 million to $1.18 billion, primarily due to a $67.6 million settlement payment[8] - The effect of exchange rate changes on cash and cash equivalents resulted in a decrease of $2,060[19] Investments and Approvals - The company has a total of eighteen ANDAs awaiting FDA approval, including four tentative approvals[6] - The company invested $25,000 in short-term bank deposits during the quarter[19] - The net cash provided by investing activities was $34,755, compared to a net cash used of $16,427 in the prior year[19] Legal and Settlements - Taro made a $67.6 million settlement payment related to the Generic Drug Pricing Antitrust Litigation[7] - The company did not repurchase any treasury stock during the quarter, contrasting with a purchase of $18,319 in the same quarter of 2021[19] Trade Receivables - The increase in trade receivables was $19,321, compared to an increase of $3,295 in the same quarter of 2021[19]